Clinical Trial Update: A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/2 dose-ranging study of lenalidomide in patients with non-5q deletion myelodysplastic syndrome (low- to intermediate-1 risk). The trial was te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Myelodysplastic Syndrome, MDS | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2014-06-03